NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 325
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into securities purchase agreements with institutional investors to raise approximately $3 million. The funding will come from the sale of 17,647,060 shares of common stock, priced at $0.17 per share, in a registered direct offering. The proceeds will be used for general corporate purposes and working capital. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction, which is expected to close today, Oct. 24, 2024, pending customary conditions.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer